In this analysis, we will do our best to explain what Tesamorelin is, how it works, and its main properties.
Tesamorelin Peptide: What is it?
The hypothalamus secretes growth hormone-releasing hormone (GHRH), which mediates communication between the endocrine and neurological systems. The anterior pituitary gland produces growth hormone (GH) in response to this hormone. [ii]
Studies suggest the synthetic peptide Tesamorelin acetate (consisting of 44 amino acids) has a structure and action similar to the growth hormone-releasing hormone (GHRH). [iii]
Research suggests that to increase its stability and pharmacodynamics; Tesamorelin makes a little modification to the N-terminal region of the Amino acids that give any peptide its distinctive features, compared to growth hormone-releasing hormone (GHRH).
Tesamorelin Peptide: How Does It Work?
Researchers speculate Tesamorelin works by potentially targeting the same receptors as the endogenous hormone it mimics. Therefore, Tesamorelin may have a highly targeted method of action.
Research suggests Tesamorelin may bind to GHRHr in the anterior pituitary, which produces growth hormone. The pituitary’s somatotrophic cells are activated to produce and release growth hormone (GH) in response to this binding.
Adipocytes (fat cells), hepatocytes (liver cells), myocytes (muscle cells), and osteoblasts (bone cells) are the primary targets of growth hormone (GH). [iv]
Studies suggest a negative feedback mechanism may be activated to keep the growth hormone (GH) released in response to Tesamorelin within parameters. Since Tesamorelin may cause the pituitary gland to secrete growth hormone (GH), it may help keep the hypothalamus and the endocrine system in sync, researchers speculate.
Tesamorelin Peptide Properties
Clinical studies suggest Tesamorelin may be used primarily to accomplish the goal of elevating GH concentrations in the blood. The Tesamorelin additional possible properties follow logically.
Lipodystrophy is a common side effect of HIV treatment and antiretroviral compounds. [v] Several studies suggested visceral adipose tissue (VAT) appeared significantly reduced in test subjects with HIV-associated lipodystrophy. Research suggests Tesamorelin may have also helped with body composition by decreasing the amount of fat around the middle, the waist, and the hips. [vi]
Carotid intima-media thickness (cIMT) has also been suggested to be decreased by Tesamorelin in research studies. Therefore, it may slow the worsening of atherosclerotic vascular disease in the carotid arteries.
Researchers speculate these potential properties might be used to support a causal relationship between Tesamorelin peptide presentation and a lower risk of cardiovascular illnesses.
Scientists hypothesize that the Insulin-like growth factor 1 (IGF-1) levels in models with lipodystrophy may be significantly reduced in the blood. They speculate that when Tesamorelin is given, the hepatocytes may start making insulin-like growth factor 1. Without affecting blood glucose levels, IGF-7 may promote development and suppress the apoptotic pathway.
Studies suggest Tesamorelin may induce lipolysis, lowering serum cholesterol and triglyceride levels. Therefore, Tesamorelin’s presentation appeared to result in better lipid profiles for the subjects receiving it.
Additional research suggested Tesamorelin was also speculated to improve the cognitive abilities of subjects over 60, putting off the inevitable deterioration in brain function. The osmolyte myoinositol (MI), responsible for the rapid cognitive decline, appeared to be possibly reduced by Tesamorelin, achieving this goal. [vii]
Tesamorelin Peptide Blends
There is insufficient evidence to recommend blending Tesamorelin with any other comparable peptide. This is due to the lack of studies for peptides structurally related to Tesamorelin, such as Ipamorelin.
However, because of its comparable mode of action and properties, studies suggest Tesamorelin may be combined with Ipamorelin to obtain optimal growth hormone (GH) release potentially.
Conclusion and Key Takeaways
Research suggests that because it may replicate the action of an endogenous hormone, Tesamorelin may also have a narrow research index. Therefore, Tesamorelin may have a highly targeted method of action.
Researchers speculate Tesamorelin may bind to GHRHr in the anterior pituitary, which may produce growth hormone. The pituitary’s somatotrophic cells are activated to produce and release growth hormone (GH) in response to this binding.
Adipocytes (fat cells), hepatocytes (liver cells), myocytes (muscle cells), and osteoblasts (bone cells) are the primary targets of growth hormone (GH).
Scientists hypothesize a negative feedback mechanism may be activated to keep the growth hormone (GH) released in response to Tesamorelin within parameters. Since Tesamorelin may cause the pituitary gland to secrete growth hormone (GH), it may also help keep the hypothalamus and the endocrine system in sync, researchers speculate.
You may find Tesamorelin for sale at Core Peptides if you are a researcher. Still, the substances discussed in this article are not approved for human consumption and should only be used in the laboratory.
References
[i] Lloyd A. HIV infection and AIDS. P N G Med J. 1996 Sep;39(3):174-80. PMID: 9795558.
[ii] Shahid Z, Asuka E, Singh G. Physiology, Hypothalamus. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535380/
[iii] LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tesamorelin. [Updated 2018 Oct 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548730/
[iv] Dehkhoda F, Lee CMM, Medina J, Brooks AJ. The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects. Front Endocrinol (Lausanne). 2018 Feb 13;9:35. doi: 10.3389/fendo.2018.00035. PMID: 29487568; PMCID: PMC5816795.
[v] Bedimo R. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl). 2011;3:69-79. doi: 10.2147/HIV.S14561. Epub 2011 Jul 10. PMID: 22096409; PMCID: PMC3218714.
[vi] Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. PMID: 21668043.
[vii] Friedman SD, Baker LD, Borson S, Jensen JE, Barsness SM, Craft S, Merriam GR, Otto RK, Novotny EJ, Vitiello MV. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013 Jul;70(7):883-90. doi: 10.1001/jamaneurol.2013.1425. PMID: 23689947; PMCID: PMC3764915.
